Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib in AKT-Mutated Advanced Cancers (MATCH Subprotocol Z1K)
NCT06400251Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipatasertib in malignant solid neoplasm, lymphoma and multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 3 years. Started Aug 2019; status: active, not recruiting.
02
Drugs
ipatasertib
03
Conditions
malignant solid neoplasmlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06400251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400251.